Subchronic toxicity studies with ginsenoside compound K delivered to dogs via intravenous administration

Food and Chemical Toxicology

Volumn 49, Issue 8, 2011, Pages 1857-1862

  Gao, Y L ^a   Liu, Z F ^a,b   Li, C M ^a,b   Shen, J Y ^a   Yin, H X ^a   Li, G S ^a,b  

^a YANTAI UNIVERSITY   (China)

^b Shandong Engineering Research Center for Nature Drug   (China)

Author keywords

ALB; ALP; ALT; AST; BUN; CK; Compound K; Dogs; Intravenous administration; Subchronic toxicity

Indexed keywords

20 O BETA DEXTRO GLUCOPYRANOSYL PROTOPANAXADIOL; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE; GINSENOSIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD CHEMISTRY; BODY TEMPERATURE; BODY WEIGHT; CHRONIC TOXICITY; CLINICAL OBSERVATION; CONTINUOUS INFUSION; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FOOD INTAKE; HEMATOLOGY; HISTOPATHOLOGY; LIVER TOXICITY; MALE; MORTALITY; NONHUMAN; ORGAN WEIGHT; SUBCHRONIC TOXICITY; TOXICITY TESTING; URINALYSIS;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; BODY WEIGHT; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ELECTROCARDIOGRAPHY; FEMALE; GINSENOSIDES; INJECTIONS, INTRAVENOUS; LIVER; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; ORGAN SIZE; PANAX; PLANT EXTRACTS; TOXICITY TESTS, CHRONIC; URINALYSIS;

ANIMALIA; CANIS FAMILIARIS; PANAX GINSENG;

EID: 79958755408     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2011.05.003     Document Type: Article

References (28)

1. Akao T., Kida H., Kanaoka M., Hattori M., Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J. Pharm. Pharmacol. 1998, 50:1155-1160.
2. Anzenbacher P., Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. 2001, 58:737-747.
3. Bae E.A., Han M.J., Choo M.K., Park S.Y., Kim D.H. Etabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol. Pharm. Bull. 2002, 25:58-63.
4. Choo M.K., Sakurai H., Kim D.H., Saiki I. Ginseng saponinmetabolite suppresses tumor necrosis factor-alpha-promotedmetastasis by suppressing nuclear factor-kappaB signaling inmurine colon cancer cells. Oncol. Rep. 2008, 19:595-600.
5. Clay P.G., Glaros A.G., Clauson K.A. Perceived efficacy, indications, and information sources for medically indigent patients and their healthcare providers regarding dietary supplements. Ann. Pharmacother. 2006, 40:427-432.
6. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Cui Y., Ang C.Y. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St. John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005, 22:525-539.
7. Hamid R., Jaouad E., Zafar H.I., Badiaa L. Acute and subchronic toxicity of an aqueous extract of the leaves of Herniaria glabra in rodents. J. Ethnopharmacol. 2008, 118:378-386.
8. Hao M., Zhao Y., Chen P., Huang H., Liu H., Jiang H., Zhang R., Wang H. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS ONE 2008, 3:e2697.
9. Hasegawa H., Sung J.H., Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponis. Planta Med. 1997, 63:436-440.
10. Hasegawa H., Sung J.H., Matsumiya S., Uchiyama M., Inouye Y., Kasai R., Yamasaki K. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Planta Med. 1995, 61:409-413.
11. Hasegawa H., Sung J.H., Matsumiya S., Uchiyama M., Uchiyama M. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med. 1996, 62:453-457.
12. Hasegawa H., Sung J.H., Huh J.H. Ginseng intestinal bacterial metabolite IH901 as a new anti-metastatic agent. Arch. Pharm. Res. 1997, 20:539-544.
13. He N., Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am. J. Ther. 2004, 11:206-212.
14. Henderson G.L., Harkey M.R., Gershwin M.E., Hackman R.M., Stern J.S., Stresser D.M. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 1999, 65:PL209-PL214.
15. Johnson J.R., Bross P., Cohen M., Rothmann M., Chen G., Zajicek A., Gobburu J., Rahman A., Staten A., Pazdur R. Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin. Cancer Res. 2003, 9:1972-1979.
16. Karikura M., Miyase T., Tanizawa H., Taniyama T., Takino Y. Studies on absorption, distribution, excretion and metabolism of ginseng saponins. VII. Comparison of the decomposition modes of ginsenoside-Rb1 and -Rb2 in the digestive tract of rats. Chem. Pharm. Bull. 1991, 39:2357-2361.
17. Kim S., Kang B.Y., Cho S.Y., Sung D.S., Chang H.K., Yeom M.H., Kim D.H., Sim Y.C., Lee Y.S. Compound K induces expression of hyaluronan synthase 2 gene in transformed human keratinocytes and increases hyaluronan in hairless mouse skin. Biochem. Biophys. Res. Commun. 2004, 316:348-355.
18. Kim M.S., Kwon B., Park M.S., Ji G.E. Isolation of ginsenoside Rh1 and compound K from fermented ginseng and efficacy assessment on systemic anaphylactic shock. Food Sci. Biotechnol. 2008, 17:805-808.
19. Kim do.Y., Yuan H.D., Chung I.K., Chung S.H. Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells. J. Agric. Food. Chem. 2009, 57:1532-1537.
20. Kumar S., Earla R., Jin M., Mitra A.K., Kumar A. Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir. Biochem. Biophys. Res. Commun. 2010, 402:163-167.
21. Lee B.H., Lee S.J., Hur J.H., Lee S., Sung J.H., Huh J.D., Moon C.K. In vitro antigenotoxic activity of novel ginseng saponin metabolites formed by intestinal bacteria. Planta Med. 1998, 64:500-503.
22. Saxena A., Tripathi K.P., Roy S., Khan F., Sharma A. Pharmacovigilance: Effects of herbal components on human drug interactions involving cytochrome P450. Bioinformation 2008, 3:198-204.
23. Shin Y.W., Bae E.A., Kim S.S., Lee Y.C., Kim D.H. Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis. Int. Immunopharmacol. 2005, 5:1183-1191.
24. Smith, M., Lin, K.M., Zheng, Y.P., 2001. An open trial of nifedipine-herb interactions: nifedipine with St. John's wort, ginseng, or Ginkgo biloba. Presented at: American Society for Clinical Pharmacology and Therapeutics annual meeting, Orlando, FL, March 6-10.
25. Tanaka N., Tanaka O., Shibata S. Chemical studies on the oriental plant drugs: XXVIII. Saponins and sapogenins of ginseng; stereochemistry of sapogenin of ginsenoside Rb1, Rb2 and Rc. Chem. Pharm. Bull. 1972, 20:1212-1216.
26. Wakabayashi C., Hasegawa H., Murata J., Saiki I. In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. Oncol. Res. 1997, 9:411-417.
27. Wakabayashi C., Murakami K., Hasegawa H., Murata J., Saiki I. An intestinal bacterial metabolite of ginseng protopanaxadiol saponins has the ability to induce apoptosis in tumor cells. Biochem. Biophys. Res. Commun. 1998, 246:725-730.
28. Wang Y., Zhou L., Dutreix C., Leroy E., Yin Q., Sethuraman V., Riviere G.J., Yin O.Q., Schran H., Shen Z.X. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br. J. Clin. Pharmacol. 2008, 65:885-892.